Alessandra Casagrande

Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial

David R. Clemmons, Yang Wang, Alessandra Casagrande, Tiffany P. Quock et autres

us (code pays fourni par la source)

Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial

David R. Clemmons, Tiffany P. Quock, Alessandra Casagrande, Yang Wang et autres

PURPOSE: To evaluate the hypothesis that breakthrough acromegaly symptom exacerbation frequency would be reduced after switching biochemically controlled patients from depot somatostatin receptor ligand (SRL) injections to once-daily oral paltusotine. METHODS: Biochemical disease control (insulin-like growth factor 1 [IGF-I]) and Acromegaly Symptom …

us (code pays fourni par la source)

Safety and efficacy of once-daily oral paltusotine in acromegaly: ACROBAT Advance open-label extension up to 4 years

Mônica R. Gadelha, Murray B. Gordon, Mirjana Doknić, Emese Mezősi et autres

CONTEXT: Paltusotine is the first non-peptide selective somatostatin 2 receptor agonist approved as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate long-term treatment with paltusotine in patients with acromegaly previously on an injected somatostatin receptor ligand (SRL)-based regimen. METHODS: ACROBAT Advance is …

br, us, rs, pl, hu, gb (code pays fourni par la source)

Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment

Beverly M. K. Biller, Alessandra Casagrande, Атанаска Еленкова, César Luiz Boguszewski et autres

CONTEXT: Paltusotine is a nonpeptide, selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate efficacy and safety of paltusotine in patients with biochemically uncontrolled acromegaly not currently receiving medical therapy. METHODS: In this phase 3, …

us, bg, br, pk, nl, de (code pays fourni par la source)

MON-069 Once-daily Oral Paltusotine In The Treatment Of Patients With Biochemically Uncontrolled Acromegaly: Interim Results Of The PATHFNDR-2 Open-label Extension

Mônica R. Gadelha, Alessandra Casagrande, Атанаска Еленкова, César Luiz Boguszewski et autres

Abstract Disclosure: M. Gadelha: Ipsen, Crinetics Pharmaceuticals, Inc., Novo Nordisk, Recordati, Camurus. A. Casagrande: Crinetics Pharmaceuticals, Inc. A. Elenkova: Pfizer, Inc., Novartis Pharmaceuticals, Novo Nordisk, Corcept Therapeutics, Crinetics Pharmaceuticals, Inc., Xeris Pharmaceuticals, Recordati Rare Diseases. C.L. Boguszewski: Crinetics Pharmaceuticals, Inc., Ipsen, Novo …

br, us, bg, nl, de (code pays fourni par la source)

OR12-07 Disease Control in Patients With Acromegaly Switching From Injected Somatostatin Receptor Ligands to Once-Daily Oral Paltusotine: Interim Results of the PATHFNDR-1 Open-Label Extension

Beverly M. K. Biller, Alessandra Casagrande, Christian Joseph Strasburger, Martin Bidlingmaier et autres

Abstract Disclosure: B.M. Biller: Crinetics Pharmaceuticals, Inc., Principal investigator of a research grant to Massachusetts General Hospital, consultant, Amolyt Pharma, Consultant, Camurus, Consultant, Chiesi, Consultant, Pfizer, Consultant, Recordati, Consultant. A. Casagrande: Crinetics Pharmaceuticals, Employee and shareholder. C.J. Strasburger: Crinetics Pharmaceuticals, Principal investigator …

us, de, ar, br, il, fr, hu, rs (code pays fourni par la source)

Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: ACROBAT advance year 4 analysis

Gadelha Monica R., Randeva Harpal S., Gordon Murray B., Mirjana Doknić et autres

12535 Efficacy And Safety Of Once-daily Oral Paltusotine In Medically Untreated Patients With Acromegaly: Results From The Phase 3, Randomized, Placebo-controlled Pathfndr-2 Study

Beverly M. K. Biller, Alessandra Casagrande, Атанаска Еленкова, César Luiz Boguszewski et autres

Abstract Disclosure: B.M. Biller: Consulting Fee; Self; Amolyt, Amryt, Camurus, Crinetics, and Recordati. Research Investigator; Self; Crinetics and Ionis. A. Casagrande: Employee; Self; Crinetics Pharmaceuticals. Stock Owner; Self; Crinetics Pharmaceuticals. A. Elenkova: Grant Recipient; Self; Pfizer, Novartis, and Novo Nordisk. Research Investigator; …

us, bg, br, nl, de (code pays fourni par la source)

12531 Long-term Safety And Efficacy Of Once-daily Oral Paltusotine In The Treatment Of Patients With Acromegaly: Update From Acrobat Advance

Mônica R. Gadelha, Harpal Singh Randeva, Murray B. Gordon, Mirjana Doknić et autres

Abstract Disclosure: M. Gadelha: Consulting Fee; Self; Crinetics, Ipsen, Novo Nordisk, and Recordati. Grant Recipient; Self; Crinetics and Recordati. Speaker; Self; Ipsen, Novo Nordisk, and Recordati. H.S. Randeva: None. M.B. Gordon: Consulting Fee; Self; Crinetics Pharmaceuticals, HRA Pharma, Novo Nordisk, and Recordati …

br, gb, us, rs, hu (code pays fourni par la source)

8404 Use of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide

Mônica R. Gadelha, Alessandra Casagrande, Christian Joseph Strasburger, Martin Bidlingmaier et autres

Abstract Disclosure: M.R. Gadelha: Consulting Fee; Self; Crinetics, Ipsen, Novo Nordisk, and Recordati. Research Investigator; Self; Crinetics and Recordati. Speaker; Self; Ipsen, Novo Nordisk, and Recordati. A. Casagrande: Employee; Self; Crinetics Pharmaceuticals. Stock Owner; Self; Crinetics Pharmaceuticals. C.J. Strasburger: Consulting Fee; Self; …

br, us, de, ar, il, fr, hu, rs (code pays fourni par la source)

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Mônica R. Gadelha, Alessandra Casagrande, Christian Joseph Strasburger, Martin Bidlingmaier et autres

CONTEXT: Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. OBJECTIVE: To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs). …

br, us, de, ar, il, fr, hu, rs, pl (code pays fourni par la source)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of oral paltusotine, a small-molecule, selective somatostatin receptor subtype 2 agonist

Rosa Luo, Alessandra Casagrande, BA Sonic Oun, M Wang et autres

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)